PMID- 38096896
OWN - NLM
STAT- MEDLINE
DCOM- 20231216
LR  - 20240222
IS  - 1365-2060 (Electronic)
IS  - 0785-3890 (Print)
IS  - 0785-3890 (Linking)
VI  - 55
IP  - 2
DP  - 2023
TI  - Health care resource use, diagnostic delay and disease burden in transthyretin 
      amyloid cardiomyopathy in Sweden.
PG  - 2292686
LID - 10.1080/07853890.2023.2292686 [doi]
LID - 2292686
AB  - AIMS: To estimate healthcare resource use and direct healthcare costs of 
      Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Sweden over 12 months across 
      severity stages as defined by the New York Heart Association (NYHA). Secondary to 
      investigate the current diagnostic trajectory for patients with ATTR-CM in 
      Sweden. METHODS: A stratified inclusion of patients with a confirmed diagnosis of 
      ATTR-CM in different NYHA classes. Data was extracted from medical records in two 
      cardiology clinics in Sweden. Healthcare resource use data were retrospectively 
      collected for 12 months. RESULTS: 38 patients were included, of whom 7 were in 
      NYHA class II, 20 in class III and 4 in class IV. The total cost of health care 
      per patient increased from SEK 69,000 (euro6800) in NYHA stage II, SEK 219,000 
      (euro21,500) in NYHA stage III, to SEK 638,000 (euro62,900) in stage IV, mainly due to 
      an increase in inpatient stays. Mean time (standard deviation, SD) from any 
      cardiac related diagnosis prior to ATTR-CM diagnosis was 3.5 (3.1) years. 
      CONCLUSIONS: Advanced ATTR-CM stages are associated with significant healthcare 
      costs, as patients more often require resource-intensive inpatient care. The 
      current diagnostic trajectory of ATTR-CM in this study was characterized by a 
      diagnostic delay of several years.
FAU - Hjalte, Frida
AU  - Hjalte F
AD  - The Swedish Institute for Health Economics, Lund, Sweden.
FAU - Norlin, Jenny M
AU  - Norlin JM
AD  - The Swedish Institute for Health Economics, Lund, Sweden.
FAU - Alverback-Labberton, Linda
AU  - Alverback-Labberton L
AD  - Pfizer AB, Stockholm, Sweden.
FAU - Johansson, Katarina
AU  - Johansson K
AD  - Pfizer AB, Stockholm, Sweden.
FAU - Wikstrom, Gerhard
AU  - Wikstrom G
AD  - Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
FAU - Eldhagen, Per
AU  - Eldhagen P
AD  - Department of Medicine Karolinska Institutet and Department of Cardiology, 
      Karolinska University Hospital, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231214
PL  - England
TA  - Ann Med
JT  - Annals of medicine
JID - 8906388
RN  - 0 (Prealbumin)
SB  - IM
MH  - Humans
MH  - *Amyloid Neuropathies, Familial/diagnosis/therapy/complications
MH  - Prealbumin
MH  - Delayed Diagnosis
MH  - Retrospective Studies
MH  - Sweden/epidemiology
MH  - Cost of Illness
MH  - *Cardiomyopathies/diagnosis/therapy
MH  - Delivery of Health Care
PMC - PMC10732175
OAB - This study shows that both healthcare resource use and healthcare costs increased 
      considerably with a higher degree of ATTR-CM severity.The diagnostic trajectory 
      of ATTR-CM in this study was characterized by a diagnostic delay of several 
      years.Greater disease awareness and a lower threshold for screening risk groups 
      for TTR-amyloidosis is prompted to establish an earlier diagnosis.
OABL- eng
OTO - NOTNLM
OT  - ATTR-CM
OT  - NYHA
OT  - costs
OT  - diagnosis
OT  - health care resources
COIS- FH and JMN have no conflict of interest to declare. KJ and LAL are employed by 
      Pfizer AB. GW conducted the Tafamidis study and has speaker honoraria from 
      Janssen Orion Pharma and Novo Nordisk. PE has Grants: Pfizer; Consultant: Pfizer, 
      Alnylam, BMS, Amicus, Sanofi; Speaker s honoraria: Pfizer, Alnylam, BMS, Amicus, 
      Orion Pharma, Sanofi.
EDAT- 2023/12/15 00:43
MHDA- 2023/12/17 09:46
PMCR- 2023/12/14
CRDT- 2023/12/14 19:03
PHST- 2023/12/17 09:46 [medline]
PHST- 2023/12/15 00:43 [pubmed]
PHST- 2023/12/14 19:03 [entrez]
PHST- 2023/12/14 00:00 [pmc-release]
AID - 2292686 [pii]
AID - 10.1080/07853890.2023.2292686 [doi]
PST - ppublish
SO  - Ann Med. 2023;55(2):2292686. doi: 10.1080/07853890.2023.2292686. Epub 2023 Dec 
      14.